

# WaveSense Appoints New National Accounts Manager

March 1, 2016

**IRVINE, Calif., Mar. 1, 2016** -- WaveSense, Inc. ([www.wavesense.com](http://www.wavesense.com)) the leader in targeted cell isolation and enrichment from liquid biopsies, announced today that Alex Wolfe has joined the firm to further develop their growing portfolio of regional and national accounts. Alex Wolfe comes with a wealth of experience within the laboratory industry, having spent 7 years as a cytogenetic technologist and the last 3 years at Applied Spectral Imaging where Alex was instrumental in developing numerous customer relationships. His arrival coincides with the launch of WaveSense's expanded suite of liquid biopsy-based hematopathology applications, including CD138+, CD34+ and CD19+.

Alex joins WaveSense as National Accounts Manager to continue WaveSense's recent success providing the most sensitive, effective and efficient cell isolation and enrichment technology to a growing number of the top cancer centers, medical institutions and reference laboratories. Alex commented "I am excited to start a new challenge within WaveSense and look forward to working with the team to further develop their growing suite of liquid biopsy applications. I am fortunate to be joining a company whose cell isolation/enrichment products are on the verge of becoming the industry-standard."

Peter Hartmayer, Executive Vice President of Sales, said "Alex's wealth of experience and industry knowledge has already made him a key addition to the WaveSense family. We view his appointment as a sign of our commitment to being the leading company in our industry. Our new innovations and the increasing demand from our customers led us to look for an addition to our team who will fit in with our ethos of innovation and exceptional service, and it is very fortunate that we were able to find someone of Alex's caliber to fulfill this role. I'm confident that Alex will play a key role in providing and implementing high quality solutions for our clients."

## About WaveSense

WaveSense, based in Irvine, CA ([www.wavesense.com](http://www.wavesense.com)) is the leader in targeted cell isolation and enrichment from liquid biopsies. WaveSense's In Vitro diagnostic (IVD) products provide the most sensitive targeted cell enrichment solution, requiring only a small specimen to deliver the maximum number of pure target cells while simultaneously eliminating background cells. Without the need for expensive capital equipment, WaveSense technology enables enhanced patient diagnostic and management outcomes by optimizing the results of downstream diagnostic modalities including IHC, FISH, PCR, SNP, Gene Expression and NGS. The WaveSense platform fulfills the need to improve workflow, test sensitivity and test results while increasing revenue and reducing operational costs and complexity. WaveSense manufactures the only IVD products for paramagnetic coupled antibody targeted cell enrichment.